Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial
Nephrology Journal Club on X: "T1h: Outcomes were defined accordingly with International Society on Thrombosis and Haemostasis @isth #NephJC https://t.co/b0tQMjYKbE" / X
MASTER DAPT | Terumo Interventional Systems
Anticoagulation strategies and clinical outcomes after bleeding events during anticoagulation therapy for venous thromboembolism in the practice-based Japanese registry | Journal of Thrombosis and Thrombolysis
MASTER-DAPT: “the MASTER of high-bleeding risk trials”
Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials | Scientific Reports
Evaluation of Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in the Oncology Population Jessica Hedvat, PharmD PGY-1 Pharmacy. - ppt download
Definition of bleeding events in studies evaluating prophylactic antithrombotic therapy in pregnant women: A systematic review and a proposal from the ISTH SSC - Tardy - 2019 - Journal of Thrombosis and
Rivaroxaban after Thrombolysis in Acute Iliofemoral Venous Thrombosis: A Randomized, Open-labeled, Multicenter Trial | Scientific Reports
Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis | European Journal of Clinical Pharmacology
Cost–utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer | CMAJ
Predictive ability of scores for bleeding risk in heart disease outpatients on warfarin in Brazil | PLOS ONE
Individual Benefits and Harms of Extended Anticoagulation in Patients with Venous Thromboembolism: The VTE-PREDICT Model - ISTH Congress Abstracts
A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor - ScienceDirect
Clinically relevant non-major bleeding and intra-cranial haemorrhage in... | Download Scientific Diagram
abelacimab for prevention of venous | PPT
Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
Identification of International Society on Thrombosis and Haemostasis major and clinically relevant non-major bleed events from electronic health records: a novel algorithm to enhance data utilisation from real-world sources | International Journal
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize. - ppt download
Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients
Long-Term Risk of Clinically Relevant Non-Major Bleeding During Extended Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-Analysis - ISTH Congress Abstracts
PACIFIC-AF: Low bleeding rates for asundexian in atrial fibrillation - Medical Conferences
Cancers | Free Full-Text | A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal,
Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial
Direct Oral Anticoagulants: A User's Guide | Consultant360
CRNM - "Clinically Relevant Non-Major Bleeding" by AcronymsAndSlang.com
